Acacia Pharma completes clinical trial with APD 405 for nausea & vomiting

08-Jan-2009 - United Kingdom

Acacia Pharma has successfully completed its first clinical trial, a Phase I study of its lead product candidate APD 405. Acacia is one of the few companies focused on supportive care, especially in patients with cancer. APD 405 is being developed for the prevention and treatment of nausea & vomiting, which remains a common problem after surgery and after treatment with many cancer chemotherapy drugs.

The trial was conducted in 29 healthy male and female volunteers and demonstrated that APD 405 is safe and well-tolerated across a range of doses. No serious adverse events occurred and no significant changes in blood chemistry, ECGs, vital signs and other clinical tests were seen. The results of the study support further development of APD 405 and a Phase II study in adult patients undergoing surgery is being prepared, with initiation planned for the first quarter of 2009.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances